iTech PostImmunotherapy Is The Cure For HIV, Research ClaimsiTech PostLong before, immunotherapy has been well-known in the field of medicine to make great strides in various diseases including cancer treatment. With the Seattle region previously ident… Continue reading
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsDove Medical PressAbstract: Nanomedicine application in cancer immunotherapy is currently one of the most challenging areas in cancer therapeutic intervention. Innova… Continue reading
Proactive Investors AustraliaCynata Therapeutics secures funds to progress stem cell technologyProactive Investors AustraliaThe company intends to use the proceeds of the placement and the FUJIFILM investment to accelerate the development of its Cymeru… Continue reading
|
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
EIN News (press release) /EINPresswire.com/ — SYDNEY, AUSTRALIA–(Marketwired – Jan 22, 2017) – Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD ) (“Prima” or the “Company”) announces that the submission titled “TACTI-mel, Two ACTive Immunotherapies in Melanoma: … |
YorkMix |
‘How did they let this once thriving York pub get in such a terrible state?’
YorkMix No wonder it attracted so few regulars at the end with its distressed gaudy carpets and matted black shiny congealed seating. There’s a state of grotesque suspended animation. It was as though the nuclear siren had wailed and people had walked out and … |
|
Zacks: CRISPR THERAPTC (CRSP) Given Average Rating of “Strong Buy” by Analysts
BBNS CRISPR THERAPTC logo Shares of CRISPR THERAPTC (NASDAQ:CRSP) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts … |